发布求助
文献互助 智能选刊 最新文献

Journal of Oncological Sciences最新文献

筛选
英文 中文
The Effect of COVID-19 Fear Level on Hospital Admissions in Cancer Patients 新冠肺炎恐惧程度对癌症患者住院率的影响
Journal of Oncological Sciences Pub Date : 2021-01-01 DOI: 10.37047/jos.2021-82113
Ö. Sever
{"title":"The Effect of COVID-19 Fear Level on Hospital Admissions in Cancer Patients","authors":"Ö. Sever","doi":"10.37047/jos.2021-82113","DOIUrl":"https://doi.org/10.37047/jos.2021-82113","url":null,"abstract":"Objective: Coronavirus disease-2019 (COVID-19) causes fear and anxiety due to its high mortality rates and high spreading rate. The purpose of this study is to investigate the effect of the level of fear of COVID-19 disease on the frequency of hospital admissions of cancer patients. Material and Methods: Fear of Coronavirus-19 Scale questionnaire was used to evaluate the fear of COVID-19 in cancer patients who were followed up and treated at Gaziantep University Department of Medical Oncology during September 1-30. The changes made by the patients in the frequency of hospital admissions were questioned. Results: It was observed that 36 of 107 patients included in the study changed the frequency of hospital admissions. However, no statistical relationship was found between the COVID-19 fear level and the change in the frequency of hospital admissions. When the factors affecting the frequency of hospital admissions were evaluated, it was observed that there was less change in the frequency of admission to hospital in patients without symptoms, with a history of surgery, receiving parenteral therapy, and with advanced disease. Conclusion: During the COVID-19 pandemic, oral treatment and being a patient under fol-low-up, having surgery, being a patient without symptoms negatively affected hospital admissions. Future studies will determine how the survival of these patients will be affected by the COVID-19 pandemic. © 2021 by Turkish Society of Medical Oncology.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69820201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
There are Two Ways of Spreading Light: To Be the Candle or the Mirror That Reflects It 传播光明有两种方式:做蜡烛或做反射光明的镜子
Journal of Oncological Sciences Pub Date : 2021-01-01 DOI: 10.37047/jos.2021-83165
E. Almuradova
{"title":"There are Two Ways of Spreading Light: To Be the Candle or the Mirror That Reflects It","authors":"E. Almuradova","doi":"10.37047/jos.2021-83165","DOIUrl":"https://doi.org/10.37047/jos.2021-83165","url":null,"abstract":"A patient with cancer should always anticipate a positive response; however, he should be aware of the correct facts. Thus, what does a patient diagnosed with triple-negative breast cancer (TNBC) think and perceive? Similar to many oncologists, the word “triple-negative” brings a mental picture of, “A disease that will be difficult to treat, relapse early, and have a very short survival when relapsed.” Although this assumption is challenging for the doctor, it is particularly terrifying for the patient. Furthermore, the effect of emotional state on survival is a well-established fact.1","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69820350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gamification as a Solution for Cancer-Induced Cognitive Impairment 游戏化作为癌症引起的认知障碍的解决方案
Journal of Oncological Sciences Pub Date : 2021-01-01 DOI: 10.37047/jos.2020-78809
Gökhan Vatansever, Tarık Keçeli̇, Önder Kırca, A. Basarir, M. Özdoğan
{"title":"Gamification as a Solution for Cancer-Induced Cognitive Impairment","authors":"Gökhan Vatansever, Tarık Keçeli̇, Önder Kırca, A. Basarir, M. Özdoğan","doi":"10.37047/jos.2020-78809","DOIUrl":"https://doi.org/10.37047/jos.2020-78809","url":null,"abstract":"creased over the past decades.1 This has, in turn, substantially increased the amount of effort required to address the side effects of cancer therapies. Healthcare professionals should proactively adopt strategies to improve the quality of life of cancer survivors and maximize their reintegration into the community and daily work routine after recovery from cancer. A significant challenge that might decelerate or prevent the social rehabilitation of cancer survivors is cancer-induced cognitive impairment, also colloquially known as “chemobrain” or “chemofog.” It has been reported that 10-40% of all cancer patients suffer from cancerinduced cognitive impairment.2 Most importantly, several cancer patients with this complication eventually quit or change their professions; around 30% fail in their previous positions within two years after cancer therapy.3,4 Cancer-induced cognitive impairment can be associated with the disease and its treatments such as chemotherapy, radiotherapy, hormone therapy, and novel anticancer treatments.5-9","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69819052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Prognostic Factors in Resected Biliary Tract Cancers and the Impact of Cytokeratin 20 Expression 胆道肿瘤切除术预后因素及细胞角蛋白20表达的影响
Journal of Oncological Sciences Pub Date : 2021-01-01 DOI: 10.37047/jos.2021-84414
I. Cil, Abdilkerim Oyman, S. Isik, M. Ayhan, I. Ökten, Mustafa YILMAZ, Melike Özçelik
{"title":"Prognostic Factors in Resected Biliary Tract Cancers and the Impact of Cytokeratin 20 Expression","authors":"I. Cil, Abdilkerim Oyman, S. Isik, M. Ayhan, I. Ökten, Mustafa YILMAZ, Melike Özçelik","doi":"10.37047/jos.2021-84414","DOIUrl":"https://doi.org/10.37047/jos.2021-84414","url":null,"abstract":"125 Biliary tract cancers (BTC) are a group of malignant tumors originating from the bile duct epithelium and include intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), and gallbladder carcinoma (GBC).1,2 They constitute 0.7% of all cancers and 3% of all gastrointestinal cancers; approximately 250,000 new patients were diagnosed in 2020.3-5 Unfortunately,70% of BTCs are unresectable at the time of diagnosis, and their 5-year survival rate ranges from 5% to 15%.6,7 Although surgery being the only definitive treatment, R0 resection is possible in only 70% of patients. Moreover, the median overall survival (OS) duration of operated patients is less than 5 years despite the usage of modern surgical methods and adjuvant therapies.8","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69821524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Machine Learning Models Predict Early Postoperative Relapse in Pancreatic Cancer 机器学习模型预测胰腺癌术后早期复发
Journal of Oncological Sciences Pub Date : 2021-01-01 DOI: 10.37047/jos.2021-84326
C. Şimşek, D. Güven, F. Ceylan, I. Y. Cakir, T. K. Şahin, Ö. Dizdar, Y. Balaban, Ş. Yalçın
{"title":"Machine Learning Models Predict Early Postoperative Relapse in Pancreatic Cancer","authors":"C. Şimşek, D. Güven, F. Ceylan, I. Y. Cakir, T. K. Şahin, Ö. Dizdar, Y. Balaban, Ş. Yalçın","doi":"10.37047/jos.2021-84326","DOIUrl":"https://doi.org/10.37047/jos.2021-84326","url":null,"abstract":"115 Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease even in the localized stage. The 5-year survival is approximately 10% in the USA, and 8085% of the patients present unresectable or metastatic cancer.1,2 Even for individuals eligible for surgery, the prognosis is dismal, with only 20% surviving 5 years.1-3 While recent advances in surgery and adjuvant chemotherapy have improved survival times, the outcomes are still far from desired. PDAC remains the fourth leading cause of cancer-related deaths in the world.4 A significant obstacle is the considerable heterogeneity of the disease and the lack of reliable clinical risk stratification. Early-stage colorectal cancer and breast cancer do not present these disadvantages, and hence, it is easy to tailor treatment selection. In the constantly changing paradigm of new treatments, it is essential to identify prediction strategies for selecting the best treatment for the right patient.5 However, current knowledge currently lacks such guiding ability.","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69820726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Prognostic Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured by 18F-FDG PET/CT in Patients with NSCLC 18F-FDG PET/CT测量非小细胞肺癌患者代谢性肿瘤体积和总病灶糖酵解的预后意义
Journal of Oncological Sciences Pub Date : 2021-01-01 DOI: 10.37047/jos.2021-86651
S. Göksel, A. Cengiz, H. Öztürk, Y. Yürekli
{"title":"The Prognostic Significance of Metabolic Tumor Volume and Total Lesion Glycolysis Measured by 18F-FDG PET/CT in Patients with NSCLC","authors":"S. Göksel, A. Cengiz, H. Öztürk, Y. Yürekli","doi":"10.37047/jos.2021-86651","DOIUrl":"https://doi.org/10.37047/jos.2021-86651","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69821751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Demographic Parameters, Disease Burden, and Cardiovascular Risk Factors in Patients Who Received Primary Prophylaxis with Dexrazoxane for Prevention of Anthracycline-Induced Cardiotoxicity 评价接受右拉唑烷一级预防以预防蒽环类药物引起的心脏毒性的患者的人口统计学参数、疾病负担和心血管危险因素
Journal of Oncological Sciences Pub Date : 2021-01-01 DOI: 10.37047/jos.2020-80963
Gülhan İPEK DENİZ, Ş. Gündüz
{"title":"Evaluation of Demographic Parameters, Disease Burden, and Cardiovascular Risk Factors in Patients Who Received Primary Prophylaxis with Dexrazoxane for Prevention of Anthracycline-Induced Cardiotoxicity","authors":"Gülhan İPEK DENİZ, Ş. Gündüz","doi":"10.37047/jos.2020-80963","DOIUrl":"https://doi.org/10.37047/jos.2020-80963","url":null,"abstract":"50 Despite advancements in oncological treatments, anthracyclines still form the basis of the treatment. Anthracycline chemotherapy plays a prominent role in treating many forms of cancer. Unfortunately, the dose-dependent and cumulative cardiotoxicity limit the use of anthracyclines.1 Cardiotoxic side effects limit their dosing, and improved cancer outcomes expose the cancer survivor to increased cardiovascular morbidity and mortality. The exact mechanism of anthracycline-induced cardiotoxicity is still unclear, although it is likely to be multifactorial. The primary mechanism of cardiotoxicity may involve direct pathways for reactive oxygen species generation and topoisomerase II, and other indirect pathways. Application of various strategies can minimize anthracycline-induced cardiotoxicity; one such method is dexrazoxane, a cardioprotective agent. Dexrazoxane has been used in cancer patients to prevent anthracycline-related cardiotoxicity since the 1980s. Dexrazoxane, an ethylene diamine tetraacetic acid, such as Evaluation of Demographic Parameters, Disease Burden, and Cardiovascular Risk Factors in Patients Who Received Primary Prophylaxis with Dexrazoxane for Prevention of Anthracycline-Induced Cardiotoxicity","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69819709","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Turkish Society of Medical Oncology COVID-19 Pandemic Advisory Board Updated Recommendations for Medical Oncologists: Included Vaccination 土耳其内科肿瘤学会COVID-19大流行咨询委员会对内科肿瘤学家的最新建议:包括疫苗接种
Journal of Oncological Sciences Pub Date : 2021-01-01 DOI: 10.37047/JOS.2021-81962
A. Sümbül, Ş. Yalçın, A. Özet, S. Ünal, O. Dizdar, H. Akbulut, A. Karaoglu, N. Karadurmuş, M. Şendur, E. Çılbır, F. Yıldız, G. Tufan, O. Sonmez, N. Turhal
{"title":"Turkish Society of Medical Oncology COVID-19 Pandemic Advisory Board Updated Recommendations for Medical Oncologists: Included Vaccination","authors":"A. Sümbül, Ş. Yalçın, A. Özet, S. Ünal, O. Dizdar, H. Akbulut, A. Karaoglu, N. Karadurmuş, M. Şendur, E. Çılbır, F. Yıldız, G. Tufan, O. Sonmez, N. Turhal","doi":"10.37047/JOS.2021-81962","DOIUrl":"https://doi.org/10.37047/JOS.2021-81962","url":null,"abstract":"","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"7 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69819929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Clinicopathological Features, Treatment Outcomes, and Prognostic Factors in Adrenocortical Carcinoma: A Single-Center Experience 肾上腺皮质癌的临床病理特征、治疗结果和预后因素:一项单中心研究
Journal of Oncological Sciences Pub Date : 2021-01-01 DOI: 10.37047/jos.2021-84514
N. Demircan, T. Akın Telli, Tuğba Başoğlu, R. Arıkan, Alper Yaşar, A. Celebı, Özkan Alan, S. Isik, Özlem Ercelep, F. Dane, P. Yumuk
{"title":"Clinicopathological Features, Treatment Outcomes, and Prognostic Factors in Adrenocortical Carcinoma: A Single-Center Experience","authors":"N. Demircan, T. Akın Telli, Tuğba Başoğlu, R. Arıkan, Alper Yaşar, A. Celebı, Özkan Alan, S. Isik, Özlem Ercelep, F. Dane, P. Yumuk","doi":"10.37047/jos.2021-84514","DOIUrl":"https://doi.org/10.37047/jos.2021-84514","url":null,"abstract":"gland is adrenocortical carcinoma (ACC). ACC is a highly rare malignancy, with an incidence of 0.7-2 per million population.1 Although a diagnosis can be made at any age, ACC more frequently affects women, and its incidence peaks in the fourth to fifth decades of life.2 ACCs are generally sporadic; however, they are occasionally observed as a component of hereditary syndromes like Li-Fraumeni or Beckwith-Wiedemann syndrome.3 Approximately 60% of patients present with symptoms owing to adrenal hormone secretion, where cortisol excess (Cushing syndrome) is the leading manifestation followed by secretion of sex hormones (primarily androgen).1,4 Non-functional ACCs cause symptoms owing to tumor burden, particularly abdominal pain and weight loss. Most ACC cases are diagnosed at an advanced stage, and 5-year survival remains below 50%.5","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69821471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer 与Miller-Payne评分相比，淋巴结对新辅助化疗的反应是乳腺癌更好的生存预测因素
Journal of Oncological Sciences Pub Date : 2021-01-01 DOI: 10.37047/jos.2020-79256
N. Ak, N. Paksoy, M. Velidedeoğlu, Z. Turna, F. Demi̇relli̇
{"title":"Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer","authors":"N. Ak, N. Paksoy, M. Velidedeoğlu, Z. Turna, F. Demi̇relli̇","doi":"10.37047/jos.2020-79256","DOIUrl":"https://doi.org/10.37047/jos.2020-79256","url":null,"abstract":"42 Neoadjuvant chemotherapy (NAC) could eliminate existing potential micrometastases and prevent the growth of occult micrometastases that originated from released tumor cells during surgery, and also allowed breast-conserving at higher rates.1 Though the main expected benefit of treatment modalities is to improve disease-free survival (DFS) and progressionfree survival, investigators are trying to translate therapeutic results into better survival rates. It is critical to avoid under-treatment or overtreatment, despite a lack of clarity in determining the extent of the therapy and aiming for the best survival results. Breast cancer has been staged using the American Joint Committee on Cancer (AJCC) Tumor, Node, and Metastasis (TNM) staging system since the first edition in 1977.2 There are different neoadjuvant response evaluation systems, and “MillerPayne Criteria” is accepted useful in various cancer centers; it is graded from 1 to 5; because the pathological examination has decision-making importance and has not been standardized yet.3 Also, the clinical course of patients with pathologic complete response (pCR) remains unclear due to conflicting results. Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer","PeriodicalId":31838,"journal":{"name":"Journal of Oncological Sciences","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69819247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信